Neuropsychology Abstract of the Day: Parkinson's Disease
Cholerton BA, Zabetian CP, Quinn JF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Edwards KL, Montine TJ, & Leverenz JB. (2013). Pacific northwest udall center of excellence clinical consortium: study design and baseline cohort characteristics. Journal of Parkinsons Disease, 3(2), 205-214. doi: 10.3233/JPD-130189.
Geriatric Research, Education, & Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA Department of Psychiatry & Behavioral Science, University of Washington School of Medicine, Seattle, WA, USA.
Background: The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. Objective: To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. Methods: Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. Results: A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p < 0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. Conclusions: The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.
PMID: 23938350 [PubMed - in process]
- Neuropsychology Abstract Of The Day: Aging
Physical Activity and Risk of Cognitive Impairment Among Oldest-Old Women. American Journal of Geriatric Psychiatry. 2013 Jul 3; Wang S, Luo X, Barnes D, Sano M, & Yaffe K.AbstractOBJECTIVES: Physical activity may reduce the risk of cognitive decline...
- Neuropsychology Abstract Of The Day: Neuropsychological Assessment
A pilot evaluation of a brief non-verbal executive function assessment in Parkinson's disease. International Journal of Geriatric Psychiatry. 2013 Jul 4; Hobson PJ, Meara RJ, & Evans RAbstractOBJECTIVE: Screening for cognitive impairment in the clinical...
- Neuropsychology Abstract Of The Day: Assessment
Variability in performance: Identifying early signs of future cognitive impairment. Neuropsychology. 2012 Jul;26(4):534-540. Authors: Gamaldo AA, An Y, Allaire JC, Kitner-Triolo MH, Zonderman AB. Abstract Objective: The current study examined whether...
- Neuropsychology Abstract Of The Day: Aging And Mci Screening
Today's recommended read deals with an important neuropsychological assessment issue in the domain of aging and the potential to identify the presence of cognitive problems that might (emphasis on "might" - such findings in a screen are not definitive)...
- Neuropsychology Abstract Of The Day: Biomakers In Alzheimer's And Mild Cognitive Impairment
Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM; for the Alzheimer's Disease Neuroimaging Initiative. CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer's...